Autopsy report · NCT03120767

Wellness Initiative at New York University

“Due to inability to enroll patients”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

NYU Langone Health

Sponsor type

University, hospital or other

Conditions

Health Promotion

Interventions

Risk and Resilience; Coordinated Wellness Programming

Participants

0

Trials that died the same way

• Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
  “due to the difficulty to enroll suitable patients” (91% match in meaning)
• Ethanol Locks for the Treatment of Central Venous Line Infections
  “inability to enroll adequate number of patients” (85% match in meaning)
• Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
  “due to poor enrolled patients” (82% match in meaning)
• Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
  “Could not enroll enough patients.” (82% match in meaning)
• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
  “difficulty of enrolling patients” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.